Targeting of type I protein kinase A to lipid rafts is required for platelet inhibition by the 3′,5′-cyclic adenosine monophosphate-signaling pathway by Naseem, K. M.. et al.
1 
Targeting of Type I Protein Kinase A to lipid rafts is required for platelet inhibition by the cAMP-
signalling pathway. 
Zaher Raslan1, Simbarashe Magwenzi1, Ahmed Aburima1, Kjetil Taskén2,3,4,5 and Khalid M Naseem1. 
1 Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull, Hull 
UK. 
2 Biotechnology Centre of Oslo and 3 K.G. Jebsen Inflammation Research Centre, University of Oslo, 
Blindern, N-0317 Oslo, Norway  
4 Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo 
University Hospital, N-0318, Oslo, Norway 
5 Department of Infectious Diseases, Oslo University Hospital, N-0407 Oslo, Norway 
Total word count: 4000 
Author for correspondence: Khalid M Naseem, Thrombosis Research Laboratory, Lab 013/014, Hardy 
Building, University of Hull, Cottingham Road, Hull, HU6 7RX.  
Tel: +441482465452,   Fax: +441482309742,  Email: Khalid.naseem@hyms.ac.uk 
E-mail: khalid.naseem@hyms.ac.uk 
This is the peer reviewed version of the following article: Raslan Z, Magwenzi S, Aburima A, Taskén 
K, Naseem KM. Targeting of type I protein kinase A to lipid rafts is required for platelet inhibition 
by the 3′,5′-cyclic adenosine monophosphate-signaling pathway. J Thromb Haemost 2015; 13: 
1721–1734, which has been published in final form at DOI: 10.1111/jth.13042.  This article may be 
used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-
archiving.
2 
Abstract 
Background: cAMP signalling modulates platelet adhesion to von Willebrand factor (vWF) through 
protein kinase A (PKA)-mediated phosphorylation of glycoprotein (GP)Ibβ  A-kinase anchoring 
proteins (AKAPs) are proposed to control the localization and substrate specificity of individual PKA 
isoforms. However, the role of PKA isoforms in regulating the phosphorylation of GPIbβ and platelet 
response to vWF is unknown. 
Objectives: We wished to determine the role of PKA isoforms in the phosphorylation of GPIbβ and 
platelet activation by vWF as a model for exploring the selective partitioning of cAMP signalling in 
platelets. 
Results:  The two isoforms of PKA in platelets, type I (PKA-I) and type II (PKA-II), were differentially 
localised, with a small pool of PKA-I found in lipid rafts. Using a combination of Far Western blotting, 
immunoprecipitation, proximity ligation assay and cAMP pull down we identified moesin as an AKAP 
that potentially localises PKA-I to rafts. Introduction of cell-permeable anchoring disruptor peptide, RI 
anchoring disruptor (RIAD-Arg11), to block PKA-I/AKAP interactions, uncoupled PKA-RI from moesin, 
displaced PKA-RI from rafts and reduced kinase activity in rafts. Examination of GPIbβ demonstrated 
that it was phosphorylated in response to low concentrations of PGI2 in a PKA-dependent manner and 
occurred primarily in lipid raft fractions. RIAD-Arg11 caused a significant reduction in raft-localised 
phosphoGPIbβ and diminished the ability of PGI2 to regulate vWF-mediated aggregation and 
thrombus formation in vitro.  
Conclusion: We propose that PKA-I-specific AKAPs in platelets including moesin, organize a selective 
localisation of PKA-I required for phosphorylation of GPIbβ and contributes to inhibition of platelet 
vWF interactions.  
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Introduction 
In healthy blood vessels excessive platelet activation is controlled by endothelial-derived prostacyclin 
(PGI2) through the formation of 3’,5’cyclic adenosine monophosphate (cAMP). PGI2 binds to its Gαs-
coupled IP receptor resulting in the activation of adenylyl cyclase and consequently the production of 
cAMP(1).  Elevations in cAMP are associated with inhibition of a number of platelet functions including 
Ca2+ mobilisation, dense granule secretion, activation of integrin αIIbβ3 and aggregation (2–4). The 
foremost effector of cAMP signalling in blood platelets is protein kinase A (PKA), of which there are 
two isoforms PKA type I (PKA-I) and PKA type II (PKA-II)(5–7). The holoenzyme PKA is composed of two 
regulatory (R) and two catalytic (cat) subunits. The phosphorylation of numerous proteins by PKA, 
including Gα13(8), inositol trisphosphate receptor (IP3R)(9), phosphodiesterase 3A (PDE3A)(10), 
RhoA(11), vasodilator activated phosphoprotein (VASP)(12),  glycoprotein GPIbβ(13), CalDAG-
GEF1(14) and potentially many others(7), is thought to be a major route of cAMP-mediated regulation 
of platelet function. However, localisation and relative contributions of the individual isoforms of PKA 
to the regulation of platelet function remain unknown.  
In many cell types cAMP/PKA signalling pathways are spatially and temporally regulated to allow 
multiple cAMP signalling networks to operate simultaneously and regulate distinct biological 
functions. The isoform-specific spatiotemporal regulation of PKA signaling is mediated by a group of 
structurally diverse, but functionally similar proteins termed A-kinase anchoring proteins 
(AKAPs)(15,16). PKA isoforms bind AKAPs through a direct interaction between a conserved 
amphipathic helix motif within all AKAPs and the docking/dimerization domain (D/D domain) of the R 
dimers of the PKA holoenzyme(16), which then focuses kinase activity on specific substrates. AKAPs 
are designated as type I or type II depending on whether they preferentially interact with PKA-I or 
PKA-II. In the absence of isoform specific pharmacological inhibitors, the uncoupling of PKA-I and -II 
from their AKAP scaffolds by cell permeable peptides have been used as an alternative strategy to 
delineate PKA isoform-specific effects and the role of AKAPs(17–20). In this study, we used these 
peptides to study PKA-mediated phosphorylation of GPIbβ as a model for examining the potential 
compartmentalisation of cAMP signalling in platelets. Our data indicate that a pool of PKA-I is localised 
to lipid raft fractions through the AKAP moesin, where the kinase can target GPIbβ 
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Experimental procedures 
Materials 
Anti-PKA-RI and PKA-RII antibodies were from BD biosciences (Oxford, UK). Anti-phospho-PKA 
substrate, recognising RRXpS/T PKA consensus motif and anti-moesin antibodies were from Cell 
Signalling Technology (Hitchen, UK). Anti-phospho-GPIbβ was a kind gift from Professor Xiaoping Du 
(University of Chicago). Anti-LAT, anti-β-tubulin and IgG control antibodies were from Upstate 
(Watford, UK). The anti-integrin β3 and anti GPIbβ were from Santa Cruz Biotechnology (Heidelberg, 
Germany). PGI2 and cAMP immunoassay kits were from Cambridge Bioscience (Cambridge, UK) and 
vWF (Heamate P) was from CSL Behring. stHt31 and PKA assay kit were from Promega. Rp-8-CPT-
cAMPS and 8AHA-2’-O-Me-cAMP-agarose beads were from Biolog (Breman, Germany). RIAD-Arg11 
(LEQYANQLADQIILEATE–R11), scrambled (scr) RIAD-Arg11 (IEKELAQQYQNADAITLE-R11) and 
recombinant FLAG-RII were synthesised as previous described(21). All other chemicals, including the 
DuolinkTM proximity ligation assay kit, were from Sigma (Poole, UK).  
 
Preparation of washed platelets.  
Blood was taken from drug-free volunteers by clean venepuncture using acid citrate dextrose (ACD; 
29.9mM sodium citrate, 113.8mM glucose, 72.6mM NaCl and 2.9mM citric acid, pH 6.4) as 
anticoagulant. Washed platelets were prepared as described previously(11).  
 
Platelet aggregation and flow studies 
For aggregation studies, washed platelets (2.5x108 platelets/ml) were treated with PGI2 and then 
stimulated with vWF/ristocetin under constant stirring conditions (900rpm) for 4minutes using a 
Chronolog light aggregometer. For aggregation under flow, washed platelets (4x108 platelets/ml) were 
treated with PGI2, labelled with DIOC6 (1µM) at 37oC for 10minutes and reconstituted with autologous 
washed red blood cells (50% v/v). Platelet accrual on vWF in reconstituted blood was examined as 
previously described(22). Where necessary platelets were incubated with PKA-AKAP inhibitory 
peptides for 1hour prior to addition of PGI2. 
 
Lipid raft preparation and subcellular fractionation 
Platelet lipid rafts were isolated based on the method of Lee(23). In brief, washed platelets (450µl; 
1x109 platelets/ml) were lysed with 2x Triton-X100 lysis buffer (20mM Tris, 100mM NaCl, 60mM 
sodium pyrophosphate, 20mM sodium glycerophosphate, 0.02% w/v sodium azide, 0.065% Triton X-
100, protease and phosphatase inhibitor cocktails, pH 8.0). Lysates were vortexed and incubated on 
ice for 30minutes. Samples were mixed with equal volumes of 80% (w/v) sucrose to give 40% (w/v) 
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final concentration. This was transferred to the bottom of an ultracentrifuge tube. 5ml of 30% (w/v) 
sucrose was layered on top followed by another 5ml layer of 5% (w/v) sucrose. Tubes were 
ultracentrifuged at 200,000g for 18hours at 4°C. Sequential twelve 1-ml fractions were collected from 
the top of each sample(23).  
For subcellular fractionation washed platelets (5x108 platelets/mL) were lysed by addition of equal 
amount of 2X fractionation buffer supplemented with protease and phosphatase inhibitors followed 
by 5 freeze-thaw cycles. Lysates were subjected to ultracentrifugation at 100,000g for 90minutes at 
4oC. Supernatants (cytosolic fraction) were aspirated and pellets (plasma and intracellular 
membranes) were resuspended with IP lysis buffer(11). Protein concentrations were measured and 
equal amounts of protein were analysed.  Fractionated platelet lysates were subjected to SDS-PAGE 
and immunoblotting. β3 was used to validate the fractionation. For quantification of raft proteins, LAT 
in fraction 5 was used as a reference for equal loading. 
 
Immunoprecipitation, cAMP pull down and immunoblotting.  
Washed platelets (3-5x108 platelets/ml) were incubated with apyrase (2U/ml), indomethacin (10µM) 
and EGTA (1mM) before treatment with PGI2.  Platelets were lysed with Laemmli buffer and proteins 
were separated by SDS-PAGE before transfer to PVDF membranes.  In some cases, platelets were 
incubated with RIAD-Arg11/scrRIAD-Arg11 or PKA inhibitors before addition of PGI2. For 
immunoprecipitation, washed platelets (8×108 platelets/ml) were lysed with ice-cold lysis buffer and 
proteins were immunoprecipitated using standard protocols(11). Proteins were separated by SDS-
PAGE and transferred to PVDF membranes.  Membranes were blocked for 60minutes with 10% BSA 
in Tris-buffered-saline-Tween (0.1%) (TBS-T), then incubated with the indicated antibody. 
Immunoblots were processed as described previously(11).For cAMP pull down experiments, platelet 
lysates were incubated with agarose-beads linked to 8AHA-2’-O-Me-cAMP, which show greater 
specificity for PKA-RI(24). Beads were incubated with lysates overnight at 4oC with mixing. Beads were 
then washed and proteins eluted by boiling in Laemmli buffer for 5minutes and analysed by SDS-PAGE 
followed by immunoblotting. In some cases, Coomassie-stained gel bands were cut out, trypsin-
digested and then analysed by MALDI-TOF mass spectrometry.    
 
PKA activity assay 
PKA activity was measured by phosphorylation (increase negative charge) of the synthetic substrate 
kemptide (Supplementary method 1).  
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PKA-RI Overlay Assay  
R overlays were conducted as previously described(25,26), using bacterially expressed and purified 
FLAG-PKA-RI. Briefly, platelet lysates were separated by SDS-PAGE and transferred to PVDF 
membranes. The membranes were blocked with 5% skimmed dry milk and 0.1% BSA in TBS-T and then 
incubated with FLAG-PKA-RI, in the presence or absence of stHt31 (20μM), overnight at room 
temperature with agitation. Membranes were washed and immunoblotted with an anti-FLAG 
antibody. Cellular proteins not binding to recombinant RI in the presence of 20μM stHt31 were 
considered putative AKAPs.  
 
cAMP measurement 
Washed platelets (2x108platelets/ml) were treated with PGI2 (50nM) for 1minute, in the presence and 
absence of inhibitors, before termination with lysis buffer. cAMP levels were assayed with a 
commercial enzyme immunoassay system and expressed as fmol cAMP/1x107 platelets.  
 
Immunofluorescence and DuolinkTM proximity ligation assay 
The cellular distribution of PKA isoforms and their interactions with other proteins were visualised by 
standard immunofluorescence or in combination with a DuolinkTM proximity ligation assay (PLA)(27) 
as described in supplementary method 2.  
 
Statistical analysis 
Results are expressed as means ± SEM and were analysed using the Student’s t-test or ANOVA. The 
results were considered significant when p values were < 0.05. 
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RESULTS 
A population of PKA-I is localized to platelet lipid rafts  
To begin to understand how cAMP signaling is localised in blood platelets we examined PKA 
phosphorylation events in distinct cellular compartments using an antibody that recognizes 
phosphorylated PKA substrates. Under basal conditions distinct phosphoproteins were observed in 
both particulate and soluble fractions (Figure 1A). Treatment with PGI2 (100nM) increased 
phosphorylated proteins in the particulate fraction with apparent molecular weights of 16, 24, 27, 40, 
48, 55, 65, 70, 100 and 120kDa. While in the soluble fractions protein with apparent molecular weights 
of 18, 27, 35, 50, 60, 70, and 120kDa were observed, suggesting that PKA may target distinct substrates 
in different compartments in platelets. Immunoblotting for PKA-I and PKA-II regulatory subunits (PKA-
RI and PKA-RII) in platelet fractions showed that PKA isoforms were present in both membrane and 
cytosolic fractions, but that PKA-I was more prominent in membrane fractions in comparison to PKA-
II (supplementary figure 1). Consistent with the subcellular fractionation data, confocal microscopy 
showed that under resting conditions PKA-RI was found primarily at the periphery of the cell, whereas 
PKA-RII staining was localised in clusters within the cytosol (Figure 1Bi and Bii).  
Recently we found a pool of AC5/6 localized in lipid rafts(28) suggesting that these cholesterol and 
sphingolipid enriched microdomains could contribute to cAMP signaling in platelets(28).  To examine 
if PKA was localised to these domains, platelet lysates were separated into lipid raft and non-lipid raft 
fractions by sucrose gradient ultracentrifugation and analysed by SDS-PAGE and immunoblotting.  The 
detergent-resistant fraction was enriched in LAT, an established raft marker, whereas the non-raft 
protein integrin β3 was excluded (Figure 1C)(23,29). Under basal conditions PKA-RI was found 
primarily in non-raft fractions, with a modest, but significant pool of PKA-RI found in the lipid raft 
fractions (Figure 1C and supplementary fig 2). In contrast, PKA-RII was found exclusively in non-raft 
fractions. Elevated cAMP concentrations triggered by PGI2 (100nM) caused small but significant 
increase in raft-localised PKA-RI, but had no effect on PKA-RII and LAT(Figure 1C). These data suggest 
that there is distinct localisation of PKA isoforms in platelets with PKA-RI the only isoform identified in 
lipid rafts. 
 
Moesin is an AKAP that binds PKA-I in platelets  
The localization of PKA isoforms is organized by AKAPs(15). To determine whether AKAPs were 
important for PKA-I localisation we adopted a four-staged strategy. Firstly, PKA-I binding proteins in 
platelets were screened using RI-overlay assay (Far Western blotting) in the presence or absence of 
StHt-31, a peptide inhibitor of PKA-AKAP interactions, to identify putative AKAPs(25).  Incubation of 
recombinant FLAG-PKA-RI with immobilised platelet lysates revealed five potential AKAPs with 
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apparent molecular masses of approximately 37, 42, 80, 100 and 140kDa (Figure 2A). We confirmed 
these findings by cAMP pull down (supplementary figure 3B). We were particularly interested in the 
80kDa band since it was the most consistent and because the Ezrin-Radixin-Moesin (ERM) family 
member Ezrin (80kDa) had previously been identified as an AKAP that binds PKA-RI in T-cell lipid 
rafts(30). Further investigation by immunoblotting showed that the band at approximately 80kDa was 
the membrane-cytoskeleton binding protein moesin (Figure 2Aii), which was confirmed by mass 
spectrometry (data not shown). Moesin has been identified as an AKAP previously(31,32) and 
therefore the second stage of our strategy sought to confirm that moesin binds PKA-RI in platelets. 
Using a cAMP pull-down to precipitate PKA-RI isoforms and associated binding proteins(24), we found 
that moesin was precipitated and therefore was potentially associated with PKA-RI (Figure 2B). While 
the cAMP coated beads we used have a higher specifically for RI than RII they do not fully discriminate 
between the two isoforms (Figure 2B) and so in a third approach we found that immunoprecipitation 
of PKA-RI from platelets led to the co-precipitation of moesin (Figure 2C). This association was 
confirmed by reverse immunoprecipitation using a moesin antibody, demonstrating the presence of 
PKA-RI and the associated PKAcat (Figure 2D and supplementary figure 4). As expected only a small 
fraction of the moesin was associated with PKA-RI. We also used a cell permeable peptide inhibitor 
that uncouples PKA-AKAP interactions. Several peptides have been developed to examine PKA-AKAP 
interactions including Ht31, RI anchoring disruptor (RIAD-Arg11) and SUPER-AKAPIS(21,33). However, 
we used RIAD-Arg11 because of its 1000-fold greater specificity for disruption of PKA-I- compared to 
PKA-II-AKAP complexes(21,33).  Incubation of platelets with FITC-RIAD-Arg11, but not FITIC-RIAD 
(without the polyarginine tail) exhibited strong fluorescence (supplementary figure 5) consistent with 
cell penetration. Pretreatment of platelets for 60minutes with RIAD-Arg11, but not scrRIAD-Arg11, 
reduced the amounts of moesin co-immunoprecipitated with PKA-RI suggesting that an interaction 
between the D/D domain of PKA-I and an amphipathic helix of moesin mediates their association 
(Figure 2C). In the fourth stage, we examined moesin-PKA-I association in intact cells using a DuolinkTM 
proximity ligation assay to visualise localisation of interacting proteins. Using immunostaining-tested 
antibodies for PKA-RI and moesin (Data not shown) and wheat germ agglutinin as a membrane marker 
we detected PLA signal around the periphery of the cell suggesting that the two proteins are 
associated near platelet plasma membrane (Figure 2E). Together these data suggest that moesin is 
localised with PKA-RI and acts as PKA-RI binding protein in platelets. 
 
 
PKA-I localises in lipid rafts through an AKAP-dependent mechanism 
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Next we wanted to examine whether the localization of PKA-RI to lipid rafts could be AKAP-mediated. 
To achieve this we disrupted PKA-I/AKAP interactions with RIAD-Arg11 and then examined lipid raft 
fractions. RIAD-Arg11 (10µM) did not affect the distribution profiles of LAT into lipid rafts, indicating 
that the raft fractions remained intact (Figure 3Ai, top panels). However, RIAD-Arg11 displaced a 
significant amount of the regulatory subunit of PKA-I from the detergent-resistant fractions (p<0.05; 
Figure 3A).  In contrast, scrRIAD-Arg11 (10µM) had no effect on the localization of PKA-RI under the 
same conditions. Similar results were obtained with StHt31 (data not shown). The data also show that 
RIAD-Arg11 (10µM) did not affect the localization of moesin (Figure 3A – bottom panels), which is 
present in small amounts in lipid raft fractions.  Consistent with raft localization of the complex the 
cholesterol-chelating agent MβCD, which disrupts lipid rafts, depleted PKA-RI and moesin from these 
fractions. cAMP pull down demonstrated that moesin was precipitated from rafts fractions as part of 
a PKA-RI complex. No moesin or PKA-RI was detected when lipid rafts were disrupted with MβCD 
(Figure 3B). Finally, we reasoned that if moesin was an AKAP binding to PKA then it should possess an 
associated PKA activity(34). Moesin was immunoprecipitated from lipid raft fractions and the ability 
to phosphorylate kemptide, a synthetic PKA substrate, examined. Immunoprecipitated moesin 
possessed a 3-fold higher PKA activity than with IgG (control) immunoprecipitates (Figure 3C). These 
data suggest that moesin in lipid rafts forms a complex with a pool of PKA-I that can facilitate 
membrane compartmentalization of the kinase. 
 
Lipid raft localised GPIbβ is phosphorylated on serine166 by PKA-I 
We next examined the importance of raft localised PKA-I to platelet activatory signaling and function. 
PGI2 (100nM) induced the phosphorylation of proteins with apparent molecular weights of 27, 100 
and 165kDa and increased the phosphorylation of the basally phosphorylated 75kDa protein (Figure 
4A) in lipid rafts, confirming kinase activity in these fractions. The phosphorylation of these proteins 
was reduced significantly when platelets were treated with RIAD-Arg11 (10µM) and abolished by the 
PKA inhibitors KT5720/Rp-8-CPT-cAMPS (10µM/500µM).  
GPIbβ is a PKA substrate, whose phosphorylation on serine166 leads to reduced vWF-mediated 
aggregation and adhesion to immobilized vWF and is found in lipid rafts(13,35,36). Using a specific 
antibody for GPIbβ we detected a band of approximately 27kDa, which corresponded to one of the 
bands detected using the phosphoPKA substrate antibody in lipid rafts. To investigate if GPIbβ could 
represent a PKA raft-localised substrate we used an antibody specific to phospho-GPIbβ-ser166. 
Consistent with previous reports we observed basal phosphorylation of GPIbβ in whole cell 
lysate(13,37). Phosphorylation was increased by PGI2 in a dose dependent manner (10-100nM) and 
restricted to basal levels by the PKA inhibitors KT5720/Rp-8-CPT-cAMPS (10µM/500µM) (Figure 4B). 
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While PKA-mediated phosphorylation of GPIbβ is associated with reduced platelet adhesion to vWF, 
the role of specific PKA isoforms in this process is unknown. In the absence of isoform-specific 
inhibitors or PKA-I deficient mice we used RIAD-Arg11 to simultaneously evaluate the role of AKAP 
coupling to PKA isoforms and partially isolate PKA-I signalling events(19,20,38). Under basal conditions 
we found no evidence of GPIbβ phosphorylation in lipid raft fractions (Figure 4C). However, treatment 
of platelets with PGI2 (100nM) led to significantly increased phosphoGPIbβ in lipid rafts (p<0.001; 
Figure 4C), with some minor effects in the non-raft fraction. The presence of RIAD-Arg11 (10µM), but 
not scrRIAD-Arg11, reduced the phosphorylation of raft-localized GPIbβ (Figure 4C). In contrast, no 
changes in phosphorylation of GPIbβ in non-raft fractions was detected. As expected a combination 
of PKA inhibitors, KT5720/Rp-8-CPT-cAMPS (10µM/500µM), abolished PGI2 stimulated 
phosphorylation in lipid rafts. Finally, we confirmed that the inhibition of PGI2-stimulated 
phosphorylation of GPIbβ by RIAD-Arg11 was at the level of PKA and not cAMP availability. Basal cAMP 
concentrations (87±37fmol/1x107 platelets) were increased to 150±52fmol/1x107platelets (p<0.05) by 
PGI2 (50nM). Pretreatment of platelets with RIAD-Arg11 (10µM) or scrRIAD-Arg11 prior to stimulation 
with PGI2, failed to affect cAMP synthesis (Figure 4D). These data could suggest that the 
phosphorylation of a population of GPIbβ in platelet lipid rafts is mediated by PKA-I and potentially 
requires its localization by an AKAP. 
 
Disruption of PKA-I anchoring diminishes the inhibitory effect of PGI2 on vWF-induced platelet 
aggregation and accrual under flow. 
Next we investigated how PKA-I uncoupling influenced platelet function. PGI2 (50nM) reduced vWF 
(20µg/mL)/ristocetin(0.75mg/ml)-mediated aggregation from 78.9±4.7 to 34±5%, but remained 
elevated at 61.8±5.8% (p<0.01, compared with PGI2 alone; Figure 5A) in the presence of RIAD-Arg11 
(2 M). ScrRIAD-Arg11 had no effect.  In control experiments, RIAD lacking the poly-Arg tail (not cell 
permeable) or the poly-Arg tail alone failed to affect the inhibition of aggregation PGI2 (data not 
shown). To further confirm the role of AKAPs we used the alternative cell permeating PKA-AKAP 
disruptor, stHt31 (Figure 5B), which disrupts anchoring of both type I and type II AKAPs(18). PGI2 
(50nM) reduced vWF/ristocetin-induced aggregation from 78.7±5.5% to 47.3±2% (p<0.05) (Figure 5B), 
although this elevated remained at 68.3±9% (p<0.05, compared to PGI2 alone; Figure 5B) with stHt31 
(2µM). In control experiments, the proline substituted stHt31P peptide (2µM) did not influence PGI2-
mediated inhibition (Figure 5B). In a series of control experiments we found that RIAD-Arg11 did not 
induce aggregation, potentiate aggregation responses induced by low dose vWF or inhibit responses 
induced by high-dose vWF (Figure 5C). Similar data were found with collagen or thrombin (data not 
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shown). These data indicate that the reduced sensitivity to PGI2 in Figure 5A and 5B was likely due to 
inhibition of PKA stimulated signaling, rather than direct platelet activation by RIAD-Arg11 alone.  
To determine if PKA-I-AKAP interactions influenced platelet function under physiological conditions, 
platelet aggregation was examined under flow.  Under arterial shear (1000s-1), immobilized vWF 
(100µg/ml) supported adhesion of numerous small aggregates that covered 29.5±2% of the vWF-
coated surface (Figure 6; supplementary video 1), which was reduced to 14±1.8% (p<0.05) by the 
presence of PGI2 (100nM) (Figure 6; supplementary video 2).  Treatment of platelets with RIAD-Arg11 
(10µM) alone did not influence platelet accrual under flow (Figure 6; supplementary video 3), but 
reversed the inhibitory effects of PGI2, with the level of surface coverage increasing to 21±3% (p<0.05 
compared to PGI2 alone) (Figure 6; supplementary video 4).  In contrast, scrRIAD-Arg11 had no effect. 
Taken together these data suggest that uncoupling of PKA-I from potential platelet AKAPs reduces the 
ability of PGI2 to inhibit vWF-mediated platelet aggregation and accrual under flow conditions. 
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Discussion  
A significant body of evidence now indicates that cAMP-mediated regulation of cellular functions is 
facilitated through isoform-specific localisation of PKA(15).  However, while cAMP signaling is an 
established mechanism for the inhibition of platelets, the PKA isoform-specific events have not been 
investigated.  Elegant studies by El Daher and colleagues demonstrated PKA can target substrates 
distributed in different cellular compartments of platelets(39) while more recently the Scholten 
laboratory has provided evidence that cAMP signalling scaffolds and AKAPs are present in 
platelets(40,41). Taken together these data suggest a level of cAMP signal compartmentalisation 
exists in platelets. In this context, we present evidence of compartmentalisation of cAMP signalling 
that contributes to regulation of vWF-mediated platelet aggregation. We demonstrate that (i) a pool 
of PKA-I, but not PKA-II, is localised to membrane lipid rafts; (ii) moesin acts as a platelet AKAP that 
targets PKA-I to lipid rafts; (iii) raft-activated PKA-I phosphorylates GPIbβ and plays a key role in the 
inhibition of vWF-stimulated platelet functions (Figure7). 
The role of individual PKA isoforms localised in distinct cellular compartments in cAMP signalling and 
regulation of platelet function has remained largely unexplored because of potential off targets of PKA 
inhibitors, the lack of isoform specific inhibitors or availability of PKA isoform null mutant mice.  
Therefore, the use of cell-permeable peptides that uncouple specific PKA isoforms from their AKAPs 
and partially isolate PKA isoform signalling events offered a strategy to begin to address this issue.  
Recently, we found that a pool of AC5/6 was located in lipid rafts suggesting that these microdomains 
played a role in cAMP signalling in platelets(28). Immunoblotting of lipid raft fractions demonstrated 
that a small pool of PKA-I, but not PKA-II, was present in rafts and was increased in response to 
elevated cAMP. Raft localisation of PKA-I was blocked by treatment of platelets with a cell permeable 
peptide designed to uncouple PKA-RI from AKAPs. Using a combination of far-western blotting, cAMP 
binding protein enrichment and immunoblotting we identified moesin as a PKA-RI binding protein, 
confirming the proteomic findings of a previous report (41). To examine if this association occurred in 
rafts we used a cAMP enrichment approach from raft fractions to isolate cAMP binding protein 
complexes(42,43). Immunoblotting of proteins precipitated from raft fractions by 8AHA-2’-O-Me-
cAMP-agarose beads(24) demonstrated the presence of moesin. The confirmation that moesin was 
acting as an AKAP was provided by two further observations. Firstly, immunoprecipitated moesin was 
complexed with both PKA-RI and PKAcat and possessed PKA catalytic activity, and secondly, the 
association of moesin and PKA-RI was blocked by treatment of platelets with RIADArg11, indicating 
that the interaction proceeded through the dimerization and docking domain of PKAR-RI. Together 
these data suggest that, consistent with other cell types, that moesin can act as an AKAP for PKA-RI in 
platelets(31,32).  
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Since only PKA-I was present in lipid rafts under the conditions investigated, we reasoned that proteins 
phosphorylated in response to PGI2 in rafts were likely PKA-I targets. Using low concentrations of PGI2 
to replicate physiologically relevant signalling and an anti-phosphoPKA substrate antibody we found 
at least four substrates with apparent molecular weights of 27, 75, 100 and 165kDa in lipid rafts. A 
simple analysis of known PKA substrates in platelets suggested the 27kDa could represent GPIbβ, 
which is also found in rafts(35,36). Immunoblotting revealed GPIbβ was phosphorylated in lipid rafts 
in response to PGI2 treatment in a PKA-dependent manner. Moreover, the uncoupling of PKA-I from 
raft fractions by RIAD-Arg11 led to diminished phosphorylation of raft GPIbβ, suggesting that 
phosphorylation of raft-localised GPIbβ is mediated by PKA type I and is facilitated by localisation of 
the kinase by an AKAP. The potential physiological significance of the AKAP-dependent PKA-I 
phosphorylation of the raft-residing GPIbβ, was demonstrated using vWF-mediated platelet 
aggregation and adhesion under flow. The uncoupling of PKA-I from its potential AKAPs partially 
reversed the inhibitory effect of PGI2 on aggregation and platelets arrest under arterial flow.  This 
approach would involve uncoupling multiple PKA-AKAP complexes in different cellular compartments, 
although the reduced of lipid raft phosphorylation of GPIbβ suggest that raft localisation of PKA-1 
could be an important factor. Interestingly, the peptide inhibitor did not prevent fully the effects PGI2 
under any of the conditions tested. This is not unexpected since the inhibition of platelet activation by 
PGI2 requires targeting of multiple aspects of platelet function, which likely involves both PKA type I 
and II.  Since PKA-II would be insensitive to the uncoupling effects of RIAD-Arg11 it would still be able 
to contribute to cAMP mediated platelet inhibition.  
Our data show the first evidence for the functional compartmentalization of PKA signalling in platelets. 
We propose that a pool of PKA-I is localised in platelet lipid rafts, potentially through interactions with 
the AKAP moesin and that this AKAP-anchored PKA-I facilitates the phosphorylation of lipid raft-
residing GPIbβ. The mechanisms facilitating the raft localisation of moesin and PKA-I are still unclear, 
but may require other adaptor proteins as is the case for ezrin in T-cells (30).  While it is likely that 
peptide disruptors such as RIAD-Arg11 uncouple numerous PKA-I-AKAP complexes in platelets, we 
believe our data demonstrate the principle of how compartmentalisation of cAMP signalling may be 
important to regulation of platelet function. However, it will be important in the future to examine 
the presence of both further PKA-I/AKAP and PKA-II/AKAP complexes and link these to the regulation 
of specific platelet functions.  
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Figure Legends.  
Figure 1: PKA isoforms have distinct subcellular localisation in platelets.  
(A) Washed platelets (5x108 platelets/ml) in the presence or absence of PGI2  (100nM, 1minute) were 
lysed and separated into soluble (S) and particulate (P) fractions.  Fractionated lysates were separated 
by SDS-PAGE and blotted for phosphoPKA substrates, PKA-RI, RII and integrin β3. Arrows indicate 
bands that are increased in response to PGI2. Immunoblots are representative of three independent 
experiments. (B) Washed platelets were fixed in-solution and spun down onto poly-L-lysine-coated 
glass coverslips. Platelets were then permeablised and stained with (i)anti PKA-RI, (ii)PKA-RII followed 
by Alexa fluor488-conjugated secondary antibody or (iii)WGA-Alexa fluor488. Images are 
representative of magnified platelets from three independent experiments. Scale bar: 2µM. (C) 
Washed platelets (1x109 platelets/ml) in the presence or absence of PGI2  (100nM, 1minute) were 
lysed with 0.065% triton X-100 lysis buffer and separated into lipid raft and non-raft fractions by 
sucrose gradient ultracentrifugation. Fractions were separated by SDS-PAGE followed by 
immunoblotting with PKA RIα/β, RIIβ subunits, SLP76 and integrin β3. (i) Blots are representative of 
five independent experiments, (ii) fold change in PKA-RI in lipid raft  and non-raft compartments 
(fraction 5 and 11, respectively). *p<0.05 compared to basal, NS: not significant. 
 
Figure 2: Moesin is a PKA-RI binding protein in platelets. 
(A)(i) Washed platelets (1x109 platelets/ml) were lysed and separated by SDS-PAGE. Resolved proteins 
were then transferred into a PVDF membrane and subjected to RI-overlay assay using recombinant 
FLAG-PKA-RI in the presence or absence of the anchoring disruptor StHt31 (20µM). Membranes were 
then immunoblotted with an antibody against the FLAG-tag. Arrow indicate potential PKA-RI-binding 
proteins in platelets. (ii) Untreated platelet lysate (WCL) proteins were resolved by SDS-PAGE and 
immunoblotted with anti-moesin antibody. Blots are representative of three independent 
experiments. (B) Washed platelets (1x109 platelets/ml) were lysed and incubated with 8AHA-2’-O-Me-
cAMP agarose beads (cAMP-Ag) or the negative control (EtOH-Ag; no cAMP) beads (20µl beads/1mg 
of protein) overnight at 4oC. Associated proteins were analysed by SDS-PAGE and immunoblotted for 
moesin, PKA-RI, PKA-RII and PKAcat. Blots are representative of four independent experiments.  (C) 
Washed platelets (5x108 platelets/ml) were lysed and subjected to immunoprecipitation using an 
antibody against PKA-RI subunit. In some cases washed platelets were treated with PGI2 (100nM for 
1min), RIAD-Arg11 (10µM), scrRIAD-Arg11 (10µM) or vehicle for 60minutes, before 
immunoprecipitation of the PKA-RI subunit. Precipitates were analysed by SDS-PAGE and 
immunoblotting using a moesin and PKA-RI antibodies. Blots are representative of four independent 
experiments. (D) As in (C) except immunoprecipitation was carried out with a moesin antibody and 
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blotted for moesin, PKA-RI and PKAcat. Blots are representative of four independent experiments. (E) 
(i-v, i’-v’) platelets were subjected to PLA to determine physical proximity of molecules as described 
in methods. Platelets were co-stained with moesin/PKA-RI antibodies (i’) or matched IgG controls (iii’). 
PKA-RI alone (ii’) and moesin alone (iv’) have been included as negative controls for the PLA, whereas 
PKA-RI/PKAcat (v’) was included as a positive control. Platelet membranes were visualised using wheat 
germ agglutinin conjugated to Alexa Fluor-488 (i-v) using fluorescence microscopy. Scale bar: 2µM.  
 
Figure 3: PKA-I and moesin are localised to lipid rafts and form a complex 
(A) Washed platelets (1x109 platelets/ml) were treated with RIAD-Arg11(10µM), scrRIAD-Arg11 (10µM) 
for 60minutes or MβCD (5mM) for 30minutes. Platelets were lysed with 0.065% triton X-100 lysis 
buffer and separated into lipid raft and non-raft fractions by sucrose gradient ultracentrifugation. 
Fractions were analysed by SDS-PAGE followed by immunoblotting with PKA RIα/β, RIIβ subunits, LAT 
and moesin. (i) Blots are representative of four independent experiments.  (ii) Densitometric analysis 
of the amount of the indicated proteins in lipid rafts (n=4). Data are represented as mean fold change 
over basal ± SEM, *p<0.05, NS: not significant. (B) Washed platelets (1x109 platelets/ml) were either 
treated with MβCD (5mM) for 30minutes or left untreated, lysed with 0.065% triton X-100 lysis buffer 
and separated into lipid raft and non-raft fractions by sucrose gradient ultracentrifugation. Fractions 
5 and 11 were then incubated with 8AHA-2’-O-Me-cAMP agarose beads (cAMP-Ag) or the negative 
control (EtOH-Ag; no cAMP) beads (20µl beads/1mg of protein) overnight at 4oC. Associated proteins 
were analysed by SDS-PAGE and immunoblotted for moesin and PKA-RI. Blots are representative of 
four independent experiments. (C) Immunoprecipitates using anti-moesin or non-specific antibody 
(IgG) from raft fraction 5 were examined for the ability to phosphorylate the synthetic PKA substrate 
kemptide to measure associated PKA activity. The assay uses a positive (+ve) control of recombinant 
PKAcat to examine enzyme activity and a negative (-ve) control where recombinant PKAcat was 
omitted. (i) A representative agarose gel image. (ii) Quantification of PKA activity where data is 
expressed as % PKA activity compared with IgG and representative of three independent experiments 
(*p<0.05 moesin compared to IgG).  
 
Figure 4: PKA-I phosphorylates GPIbβ in platelet lipid rafts in an AKAP-dependent manner.  
(A)(i) Washed platelets (1x109/ml), in the presence and absence of PGI2  (100nM, 1minute), were lysed 
with 0.065% triton X-100 lysis buffer and separated into lipid raft and non-raft fractions by sucrose 
gradient ultracentrifugation. In some cases platelets were incubated with RIAD-Arg11 (10µM, 
60minutes) or KT5720/Rp-8-CPT-cAMPS (10/500µM, 15minutes). Lipid rafts were separated by SDS-
PAGE followed by immunoblotting with phosphoPKA substrate antibody. (ii) whole cell lysates (WCL) 
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were immunoblotting for GPIbβ Blots are representative of four independent experiments. (B) 
Washed platelets (3x108/ml) were treated with PGI2 (0-100nM, 1minute), or KT5720/Rp-8-CPT-cAMPS 
(10/500µM, 15minutes) followed by PGI2. Platelets were lysed then separated by SDS-PAGE and 
blotted with phosphoGPIbβ-ser166, phosphoVASP-ser157 and β-tubulin. (i) Blots are representative 
of three independent experiments. (ii) Densitometric analysis of phosphoGPIbβ of three independent 
experiments (n=3) and expressed as mean fold change over basal ± SEM. *p<0.05 for PGI2 compared 
to basal or PGI2 in the presence or absence of KT5720/Rp-8-CPT-cAMPS. (C) Washed platelets 
(1x109/ml) were left untreated, treated with PGI2 (100nM, 1minute) alone, or in the presence of RIAD-
Arg11 (10µM, 60minutes), scrRIAD-Arg11 (10µM, 60minutes) or KT5720/Rp-8-CPT-cAMPS (10/500µM, 
15minutes). Platelets were lysed with 0.065% triton X-100 then separated into lipid raft and non-raft 
fractions by sucrose gradient ultracentrifugation. Fraction proteins were analysed by SDS-PAGE 
followed by immunoblotting with PKA-RI or phosphoGPIbβ-ser166 antibodies followed by the raft and 
non-raft markers LAT and integrin β3, respectively. (i) Representative blots of three independent 
experiments. (ii) Densitometric analysis of phosphoGPIbβ-ser166 present in lipid rafts and non-raft 
fractions (fraction 5 and 11, respectively) (n=3). Data are expressed as mean fold change ± SEM, 
*p<0.05. (D) Platelets (2x108/ml) were pre-incubated with vehicle, RIAD-Arg11 (10μM) or scrRIAD-
Arg11 (10μM) for 60minutes followed by treatment with PGI2 (50nM) (grey bars) or vehicle (black bars) 
for 1minute. cAMP levels were measured as per manufacturer’s instructions and expressed as fmol 
cAMP/1x107 platelets. Data are presented as means ± SEM of 3 individual experiments. *p<0.05 PGI2 
treatment compared to basal cAMP. 
 
Figure 5: PKA-AKAP uncoupling peptides modulate inhibition of platelet aggregation by PGI2. 
(A) Washed platelets (2.5x108/ml) were pre-incubated with RIAD-Arg11 (1-10μM), scrRIAD-Arg11 
(10µM) or vehicle for 60minutes followed by addition of PGI2 (50nM) for 1minute and then stimulated 
with vWF/Ristocetin (20µg/ml, 0.75mg/ml) for 4 minutes under stirring conditions (i) Representative 
aggregation traces, (ii) Collated data of four independent experiments expressed as mean ± SEM . # 
p<0.01 compared to absence of PGI2; *p<0.05 compared to PGI2 alone. (B) As in (A) except platelets 
were pre-treated with StHt31(2μM) or StHt31P(2µM, negative control) or vehicle for 60minutes, (i) 
Representative aggregation traces, (ii) Collated data of four independent experiments expressed as 
mean ± SEM . # p<0.01 compared to absence of PGI2; *p<0.05 compared to the presence or absence 
of StHt31P; § p<0.05 basal compared to PGI2/StHt31P (C) Washed platelets (2.5x108/ml) were 
pretreated with vehicle or RIAD-Arg11 (1, 10μM for 60minutes) then stimulated with (i) vWF/Ristocetin 
(10 µg/ml, 0.75mg/ml) or (ii) vWF/Ristocetin (20µg/ml, 0.75mg/ml). (iii) Washed platelets were 
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incubated with RIAD-Arg11 (10µM for 60minutes) or scrRIAD-Arg11 (10µM for 60minutes) alone and 
aggregation was evaluated. Shown are representative traces of three independent experiments. 
 
Figure 6: RIAD-Arg11 modulates PGI2-mediated inhibition of platelet arrest to vWF under conditions 
of flow. 
Washed platelets were pre-incubated with either RIAD-Arg11 (10μM) or scrRIAD-Arg11 (10μM) for 
60minutes followed by PGI2 (100nM) for 1minute. Platelets were recombined with autologous RBC 
and the reconstituted blood was flowed over immobilised vWF (100µg/ml), for 4minutes at 1000s-1 
and resulting platelet aggregates were viewed by fluorescent microscopy. (A) Representative images 
from 4 independent experiments and (B) % surface area coverage. Data are shown as % area coverage 
and are expressed as means ± SEM of 4 experiments. * p<0.05 and NS: not significant. 
 
Figure 7: A model of the AKAP-dependent localisation of PKA-I into platelet lipid rafts and the resultant 
phosphorylation of GPIbβ.  For clarity, GPIbα, GPV and GPXI have been omitted. In the top panel a 
pool of PKAI is localised to lipid rafts by the AKAP moesin facilitated the phosphorylation of GPIbβ. In 
the bottom panel the inclusion of the anchoring disruptor peptide, RIAD-Arg11, uncouples PKAI from 
its AKAP and thereby prevents phosphorylation of GPIbβ.   
